公开(公告)号：US12226409B2

公开(公告)日：2025-02-18

申请号：US17407742

申请日：2021-08-20

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Toshiyuki Tamai

IPC: A61K31/47 ,  A61K9/48 ,  A61P35/00

Abstract: This disclosure provides methods for treating a hepatocellular carcinoma (e.g., unresectable HCC) with lenvatinib or a pharmaceutically acceptable salt thereof. Also encompassed by the disclosure are dosage regimens described herein of lenvatinib or a pharmaceutically acceptable salt thereof for use in treating hepatocellular carcinoma (e.g., unresectable hepatocellular carcinoma) according to any of the methods described herein. Particularly useful dosages and dose modifications upon the occurrence of an adverse event or events are also disclosed.

公开(公告)号：US20190000829A1

公开(公告)日：2019-01-03

申请号：US15748980

申请日：2016-08-17

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Junji Matsui ,  Masahiro Matsuki ,  Akihiko Tsuruoka ,  Toshiyuki Tamai ,  Ryo Nakajima ,  Takuya Suzuki

IPC: A61K31/47 ,  A61P35/00 ,  A61K31/095

Abstract: A therapeutic agent for biliary tract cancer comprising 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide or a pharmacologically acceptable salt thereof is provided.